1. |
Proposed mechanism of corticosteroid resistance in COPD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
Non-nicotine smoking cessation therapies |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
The first clinical management guidelines ever to address the treatment of patients with severe sepsis have been developed. |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Tazarotene the clear winner for acne vulgaris |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 5-6
&NA;,
Preview
|
|
摘要:
Acne vulgaris is one of the skin complaints seen most frequently by physicians, and is in fact the most common skin disease in the US today. Around 67−100% of adolescents, and a substantial number of adults, have acne. Excessive follicular keratanisation, sebum production, bacterial proliferation and inflammation are the key factors involved in the pathogenesis of the disease. Treatments to date have largely consisted of topical agents, including antibacterials and, more recently, retinoids such as oral isotretinoin. Efficacy is an obvious outcome measure for the treatment of such a condition. However, severe acne can be disfiguring and can lead to significant scarring, and the presence of acne (particularly facial acne) is often associated with negative psychological effects, including depression, anxiety and poor self-image. Therefore, the consideration of QOL and patient satisfaction are clearly also important. Tazarotene, the first of a new generation of receptor-specific retinoids, has been shown to minimize the adverse effects often observed with isotretinoin. Its relative efficacy, effect on QOL and economic consequences were considered in a number of posters presented at the 62nd Annual Meeting of the American Academy of Dermatology (AAD) [Washington, DC, US; February 2004].
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
PEP programme on the money for HIV infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
Lysosomal acid lipase for atherosclerosis? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
Antiadhesion therapy may have potential in asthma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
Methotrexate-eluting stents for treating restenosis? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
Chemotherapy regimens compared for Hodgkin's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
Axillary hyperhidrosis no sweat for Botox |
|
Inpharma Weekly,
Volume &NA;,
Issue 1427,
2004,
Page 11-12
RM Poole,
Preview
|
|
摘要:
Botulinum toxin type A [Botox] is effective and well tolerated when used in the treatment of axillary hyperhidrosis, according to results from a 52-week study presented at the 62nd Annual Meeting of the American Academy of Dermatology [Washington DC, US; February 2004]. Significant improvements in the severity of hyperhidrosis, relative to baseline, were achieved in 75% of patients after a single treatment with Botox, and in up to 85% of patients after a second treatment. Furthermore, QOL, including social, emotional and occupational function, improved markedly in patients treated with Botox."Most people don't realize that hyperhidrosis is an extremely debilitating chronic condition,"said Dr Dee Anna Glaser from Saint Louis University School of Medicine, US."As such, the results of this 52-week study... are very exciting because they mean we are that much closer to having the first truly effective, non-surgical treatment available to meet the needs of patients who suffer from primary axillary hyperhidrosis".
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|